Results

Total Results: 156 records

Showing results for "lung".
Users also searched for: lung cancer screening

41. Hypertension Screening for Children Who Are Overweight or Obese: Technical Specifications (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-0232-technicalspecs.pdf
    February 04, 2020 - Blood Pressure The percentile ranking based on the National Heart Lung and Blood Guidelines, Percentile

42. Transcranial Doppler (TCD) Ultrasonography Screening for Children with SCD; and Appropriate Antibiotic Prophylaxis (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra-1416-p007-2-ef.pdf
    November 01, 2015 - disease (SCD) is one of the most common genetic disorders in the United States.1 The National Heart, Lung … Pediatrics 2011; 128(6):e1552-1574. 2National Heart, Lung and Blood Institute.

43. Inhaled Corticosteroids for Children With Persistent Asthma Prescribed at Time of Discharge From the Emergency Department (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-212-fullreport.pdf
    September 01, 2018 - Accessed August 15, 2018. 25 American Lung Association. … State of lung disease in diverse communities, 2010. … Bethesda, MD: National Heart, Lung, and Blood Institute; 2014. … National Heart, Lung, and Blood Institute. … National Heart, Lung, and Blood Institute (NHLBI).

44. Introduction | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/pqmp/implementation-qi/toolkit/asthma/introduction.html
    July 01, 2021 - strategies to reduce unnecessary pediatric asthma ED use, and Improving adherence to National Heart, Lung

45. Section 5, Table 4 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-216-section-5-table-4.pdf
    January 01, 2011 - III National Heart Lung and Blood Institute. The Management of Sickle Cell Disease.

46. Graphics for Section 5. Evidence or Other Justification for the Focus of the Measure (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-135-graphics-section-5.pdf
    November 26, 2013 - III National Heart Lung and Blood Institute. The Management of Sickle Cell Disease.

47. PowerPoint Presentation
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/evidencenow/heart-health/smoking-resources-help-quit.pptx
    August 27, 2018 - were vetted with multiple stakeholders, including The HHS Cessation Workgroup The 5 As The American Lung

48. Section 5.A, Table 4 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-0138-section-5a.pdf
    December 01, 2013 - III National Heart Lung and Blood Institute. The Management of Sickle Cell Disease.

49. L | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/topics/l.html
    April 22, 2024 - Skip to main content An official website of the Department of Health and Human Services Careers Contact Us Español FAQs Search all AHRQ sites Search small Search Menu …

50. Section 1, Tables 1 and 2 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-tables-1-2.pdf
    February 12, 2018 - temperature gap > 3°C Respiratory • PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung

51. Section 1, Tables 1 and 2 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-0231-section-1-tables-1-2.pdf
    April 26, 2018 - temperature gap > 3°C Respiratory • PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung

52. Section 1, Tables 1 and 2 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-section-1-tables-1-2.pdf
    February 09, 2018 - gap > 3°C Respiratory • PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung

53. Treating Tobacco Use and Dependence: 2008 Update by HHS Panel | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/evidencenow/heart-health/smoking/treatment.html
    August 01, 2018 - Centers for Disease Control and Prevention (CDC); National Cancer Institute (NCI); National Heart, Lung

54. Blood Pressure Control Evidence and Resources | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/evidencenow/projects/heart-health/evidence/blood-pressure.html
    March 01, 2021 - evidence on managing high blood pressure was conducted by an expert panel convened by the National Heart, Lung … This comprehensive evidence report from the Cholesterol Expert Panel convened by the National Heart, Lung

55. Strategies to Improve Asthma Care and Treatment in Primary Care Practices (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/toolkits/vchip-strategies-for-kdd.pdf
    February 01, 2015 - (2) National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and Prevention Expert

56. Overview | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/pqmp/implementation-qi/toolkit/asthma/overview.html
    July 01, 2021 - achieved by working with primary care learning collaboratives to improve adherence to National Heart, Lung

57. Key Driver Diagram | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/pqmp/implementation-qi/toolkit/asthma/key-drivers.html
    July 01, 2021 - It was designed for practices with prior QI experience and already adhering to National Heart, Lung,

58. Topic: Use of Numbers | Agency for Healthcare Research and Quality
    www.talkingquality.ahrq.gov/health-literacy/patient-education/pemat5.html
    November 01, 2020 - Taken from National Heart, Lung, and Blood Institute, Body Mass Index Table 1 http://www.nhlbi.nih.gov

59. Section 1, Tables 1 to 3 (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-0230-section-1-tables-1-3.pdf
    April 25, 2018 - temperature gap > 3°C Respiratory • PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung

60. Sepsis in the ED Detailed Measure, Technical Specifications (pdf file)
    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-detailed_measure-specs.pdf
    August 01, 2014 - gap > 3°C Respiratory • PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung